Compare HSAI & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HSAI | CRNX |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.9B |
| IPO Year | 2021 | 2018 |
| Metric | HSAI | CRNX |
|---|---|---|
| Price | $20.51 | $36.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $31.58 | ★ $76.75 |
| AVG Volume (30 Days) | ★ 1.5M | 1.3M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,039,000.00 |
| Revenue This Year | $46.29 | $720.10 |
| Revenue Next Year | $41.32 | $184.67 |
| P/E Ratio | $61.18 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.69 | $25.83 |
| 52 Week High | $30.85 | $57.99 |
| Indicator | HSAI | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 42.53 | 45.79 |
| Support Level | $17.56 | $33.19 |
| Resistance Level | $24.30 | $37.23 |
| Average True Range (ATR) | 1.16 | 2.27 |
| MACD | -0.19 | -0.24 |
| Stochastic Oscillator | 19.08 | 29.50 |
Hesai Group is engaged in the development, manufacture, and sales of three-dimensional light detection and ranging solutions, or LiDAR. Its LiDAR products enable a broad spectrum of applications across passenger or commercial vehicles with enhanced advanced driver assistance systems, or ADAS, autonomous vehicle fleets providing passenger and freight mobility services, or Autonomous Mobility, and other applications such as last-mile delivery robots, street sweeping robots, and logistics robots in restricted areas, or Robotics. Geographically, the company operates in North America, Mainland China, Europe, and Other regions.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.